Despite the overall heterogeneity, the non-prospective comparison according to PD-L1, and the fact that ORR according to this biomarker was not determined in all treated patients, the results reported herein show that patients affected by melanoma, NSCLC and genitourinary with positive PD-L1 on tumor cells may have a higher chance of response to nivolumab, pembrolizumab, and (with limited confidence) MPDL3280A in comparison to PD-L1 negative tumor. This evidence concerns the gene CD274 and neoplasm.